Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.

Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA.

Mol Cancer Res. 2018 Jul 10. doi: 10.1158/1541-7786.MCR-18-0410. [Epub ahead of print]

PMID:
29991529
2.

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).

Welti J, Sharp A, Yuan W, Dolling D, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, Crespo M, Sumanasuriya S, Ning J, Knight E, Francis JC, Hughes A, Halsey WS, Paschalis A, Mani RS, Raj GV, Plymate SR, Carreira S, Boysen G, Chinnaiyan AM, Swain A, de Bono JS; International SU2C/PCF Prostate Cancer Dream Team.

Clin Cancer Res. 2018 Jul 1;24(13):3149-3162. doi: 10.1158/1078-0432.CCR-17-3571. Epub 2018 Mar 19.

PMID:
29555663
3.

Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer.

Nassar ZD, Aref AT, Miladinovic D, Mah CY, Raj GV, Hoy AJ, Butler LM.

BJU Int. 2018 May;121 Suppl 3:9-21. doi: 10.1111/bju.14173. Epub 2018 Mar 26. Review.

4.

A new class of agents for estrogen-receptor-positive breast cancer.

Ekoue DN, Unni N, Raj GV.

Expert Rev Clin Pharmacol. 2018 Apr;11(4):325-328. doi: 10.1080/17512433.2018.1439736. No abstract available.

PMID:
29439601
5.

Electrical Impedance Measurements of Biological Cells in Response to External Stimuli.

Mansoorifar A, Koklu A, Ma S, Raj GV, Beskok A.

Anal Chem. 2018 Apr 3;90(7):4320-4327. doi: 10.1021/acs.analchem.7b05392. Epub 2018 Feb 14.

PMID:
29402081
6.

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.

Li X, Baek G, Ramanand SG, Sharp A, Gao Y, Yuan W, Welti J, Rodrigues DN, Dolling D, Figueiredo I, Sumanasuriya S, Crespo M, Aslam A, Li R, Yin Y, Mukherjee B, Kanchwala M, Hughes AM, Halsey WS, Chiang CM, Xing C, Raj GV, Burma S, de Bono J, Mani RS.

Cell Rep. 2018 Jan 16;22(3):796-808. doi: 10.1016/j.celrep.2017.12.078.

7.

Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis.

Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A.

Urol Oncol. 2018 Apr;36(4):159.e7-159.e17. doi: 10.1016/j.urolonc.2017.12.001. Epub 2017 Dec 26.

PMID:
29288008
8.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16.

PMID:
29258679
9.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

PMID:
29236593
10.

Tissue-based biomarkers in prostate cancer.

Clinton TN, Bagrodia A, Lotan Y, Margulis V, Raj GV, Woldu SL.

Expert Rev Precis Med Drug Dev. 2017;2(5):249-260. doi: 10.1080/23808993.2017.1372687. Epub 2017 Sep 5.

11.

Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses.

Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga Y, Margulis V, Bagrodia A.

Urology. 2018 Feb;112:103-111. doi: 10.1016/j.urology.2017.08.059. Epub 2017 Dec 6.

PMID:
29079210
12.

Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer.

Zhou H, Hallac RR, Yuan Q, Ding Y, Zhang Z, Xie XJ, Francis F, Roehrborn CG, Sims RD, Costa DN, Raj GV, Mason RP.

Diagnostics (Basel). 2017 Aug 24;7(3). pii: E48. doi: 10.3390/diagnostics7030048.

13.

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK.

Elife. 2017 Aug 8;6. pii: e26857. doi: 10.7554/eLife.26857.

14.

Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.

Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV.

Cancer Res. 2017 Sep 15;77(18):4745-4754. doi: 10.1158/0008-5472.CAN-17-0164. Epub 2017 Jul 28.

PMID:
28754673
15.

Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.

Clinton TN, Woldu SL, Raj GV.

Expert Opin Pharmacother. 2017 Jun;18(8):825-832. doi: 10.1080/14656566.2017.1328056. Epub 2017 May 19. Review.

PMID:
28480768
16.

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.

Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, Fernandes R, Hanson AR, Denis I, Carroll JS, Dehm SM, Raj GV, Plymate SR, Tilley WD, Selth LA.

Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.

17.

Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer.

Miao L, Yang L, Li R, Rodrigues DN, Crespo M, Hsieh JT, Tilley WD, de Bono J, Selth LA, Raj GV.

Cancer Res. 2017 Jun 1;77(11):3101-3112. doi: 10.1158/0008-5472.CAN-16-2169. Epub 2017 Mar 16.

18.

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.

Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, Ma S, Landman SR, Kumar V, Hwang TH, Raj GV, Higano CS, Morrissey C, Nelson PS, Plymate SR, Dehm SM.

Nat Commun. 2016 Nov 29;7:13668. doi: 10.1038/ncomms13668.

19.

Surgery: The surgeon-scientist - a dying breed?

Woldu SL, Raj GV.

Nat Rev Urol. 2016 Dec;13(12):698-699. doi: 10.1038/nrurol.2016.236. Epub 2016 Nov 22. No abstract available.

PMID:
27872479
20.

The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.

Wang S, Kollipara RK, Humphries CG, Ma SH, Hutchinson R, Li R, Siddiqui J, Tomlins SA, Raj GV, Kittler R.

Oncotarget. 2016 Oct 4;7(40):64921-64931. doi: 10.18632/oncotarget.11915.

21.

Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor.

Zhang B, Kwon OJ, Henry G, Malewska A, Wei X, Zhang L, Brinkley W, Zhang Y, Castro PD, Titus M, Chen R, Sayeeduddin M, Raj GV, Mauck R, Roehrborn C, Creighton CJ, Strand DW, Ittmann MM, Xin L.

Mol Cell. 2016 Sep 15;63(6):976-89. doi: 10.1016/j.molcel.2016.07.025. Epub 2016 Sep 1.

22.

Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.

Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL.

Sci Adv. 2016 Jun 24;2(6):e1501924. doi: 10.1126/sciadv.1501924. eCollection 2016 Jun.

23.

The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance.

Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, Raj GV, Sagalowsky AI, Cadeddu JA.

J Urol. 2016 Aug;196(2):321-6. doi: 10.1016/j.juro.2016.02.068. Epub 2016 Feb 13.

PMID:
26880407
24.

Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?

Cost NG, Caldwell BT, Adibi M, Raj GV, Sagalowsky AI, Margulis V.

J Adolesc Young Adult Oncol. 2016 Sep;5(3):248-53. doi: 10.1089/jayao.2015.0057. Epub 2016 Feb 12.

PMID:
26871870
25.

Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.

Regan Anderson TM, Ma SH, Raj GV, Cidlowski JA, Helle TM, Knutson TP, Krutilina RI, Seagroves TN, Lange CA.

Cancer Res. 2016 Mar 15;76(6):1653-63. doi: 10.1158/0008-5472.CAN-15-2510. Epub 2016 Jan 29.

26.

Mouse Spermatogenesis Requires Classical and Nonclassical Testosterone Signaling.

Toocheck C, Clister T, Shupe J, Crum C, Ravindranathan P, Lee TK, Ahn JM, Raj GV, Sukhwani M, Orwig KE, Walker WH.

Biol Reprod. 2016 Jan;94(1):11. doi: 10.1095/biolreprod.115.132068. Epub 2015 Nov 25.

27.

Expression of androgen receptor splice variants in clinical breast cancers.

Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, Bradley RK, Tilley WD, Selth LA.

Oncotarget. 2015 Dec 29;6(42):44728-44. doi: 10.18632/oncotarget.6296.

28.

Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma.

Haddad AQ, Jiang L, Cadeddu JA, Lotan Y, Gahan JC, Hynan LS, Gupta N, Raj GV, Sagalowsky AI, Margulis V.

Urology. 2015 Dec;86(6):1146-52. doi: 10.1016/j.urology.2015.09.015. Epub 2015 Sep 28.

PMID:
26416007
29.

KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.

Duan L, Rai G, Roggero C, Zhang QJ, Wei Q, Ma SH, Zhou Y, Santoyo J, Martinez ED, Xiao G, Raj GV, Jadhav A, Simeonov A, Maloney DJ, Rizo J, Hsieh JT, Liu ZP.

Chem Biol. 2015 Sep 17;22(9):1185-96. doi: 10.1016/j.chembiol.2015.08.007. Epub 2015 Sep 10.

30.

Management of Female Anterior Urethral Masses.

Mehta S, Sheth K, Khatri G, Raj GV, Zimmern PE.

Female Pelvic Med Reconstr Surg. 2015 Sep-Oct;21(5):e46-8. doi: 10.1097/SPV.0000000000000175.

PMID:
26313497
31.

Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.

Krabbe LM, Westerman ME, Margulis V, Raj GV, Sagalowsky AI, Courtney K, Arriaga Y, Lotan Y.

Can J Urol. 2015 Aug;22(4):7865-75.

PMID:
26267024
32.

Corrigendum: Progesterone receptor modulates ERα action in breast cancer.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS.

Nature. 2015 Oct 1;526(7571):144. doi: 10.1038/nature14959. Epub 2015 Aug 5. No abstract available.

PMID:
26245370
33.

Minireview: Deciphering the Cellular Functions of PELP1.

Ravindranathan P, Lange CA, Raj GV.

Mol Endocrinol. 2015 Sep;29(9):1222-9. doi: 10.1210/me.2015-1049. Epub 2015 Jul 9. Review. No abstract available.

34.

Progesterone receptor modulates ERα action in breast cancer.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS.

Nature. 2015 Jul 16;523(7560):313-7. doi: 10.1038/nature14583. Epub 2015 Jul 8. Erratum in: Nature. 2015 Oct 1;526(7571):144. Serandour, Aurelien A A[Corrected to Serandour, Aurelien A].

35.

A comprehensive review on clinical applications of comet assay.

Gunasekarana V, Raj GV, Chand P.

J Clin Diagn Res. 2015 Mar;9(3):GE01-5. doi: 10.7860/JCDR/2015/12062.5622. Epub 2015 Mar 1. Review.

36.

Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.

Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM.

Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.

37.

Association of distance to treatment facility on quality and survival outcomes after radical cystectomy for bladder cancer.

Haddad AQ, Singla N, Gupta N, Raj GV, Sagalowsky AI, Margulis V, Lotan Y.

Urology. 2015 Apr;85(4):876-82. doi: 10.1016/j.urology.2014.12.024.

PMID:
25817110
38.

EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.

Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA, Dehm SM.

Oncotarget. 2015 Feb 28;6(6):3811-24.

39.

An Extended Time Frame for VTE Risk in Bladder Cancer.

Raj GV, Araghizadeh F.

Oncology (Williston Park). 2014 Oct;28(10):861-2. No abstract available.

40.

The social network of PELP1 and its implications in breast and prostate cancers.

Gonugunta VK, Miao L, Sareddy GR, Ravindranathan P, Vadlamudi R, Raj GV.

Endocr Relat Cancer. 2014 Aug;21(4):T79-86. doi: 10.1530/ERC-13-0502. Epub 2014 May 23. Review.

41.

NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.

Grabowska MM, Elliott AD, DeGraff DJ, Anderson PD, Anumanthan G, Yamashita H, Sun Q, Friedman DB, Hachey DL, Yu X, Sheehan JH, Ahn JM, Raj GV, Piston DW, Gronostajski RM, Matusik RJ.

Mol Endocrinol. 2014 Jun;28(6):949-64. doi: 10.1210/me.2013-1213. Epub 2014 May 6.

42.

Emerging therapies in castration resistant prostate cancer.

Thoreson GR, Gayed BA, Chung PH, Raj GV.

Can J Urol. 2014 Apr;21(2 Supp 1):98-105. Review.

43.

Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors.

Cost NG, Lubahn JD, Adibi M, Romman A, Wickiser JE, Raj GV, Sagalowsky AI, Margulis V.

J Urol. 2014 May;191(5 Suppl):1485-90. doi: 10.1016/j.juro.2013.08.047. Epub 2014 Mar 26.

PMID:
24679874
44.

Tailoring peptidomimetics for targeting protein-protein interactions.

Akram ON, DeGraff DJ, Sheehan JH, Tilley WD, Matusik RJ, Ahn JM, Raj GV.

Mol Cancer Res. 2014 Jul;12(7):967-78. doi: 10.1158/1541-7786.MCR-13-0611. Epub 2014 Mar 18. Review.

45.

Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.

Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4251-6. doi: 10.1073/pnas.1322198111. Epub 2014 Mar 3.

46.

Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.

Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA.

Oncogene. 2015 Jan 22;34(4):506-15. doi: 10.1038/onc.2013.579. Epub 2014 Jan 27.

47.

Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature.

Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Khalil D, Kapur P, Shariat SF, Raj GV, Sagalowsky AI, Cadeddu JA, Lotan Y, Margulis V.

Urol Oncol. 2014 Jan;32(1):54.e19-26. doi: 10.1016/j.urolonc.2013.08.032.

PMID:
24360665
48.

Emerging drugs for prostate cancer.

Chung PH, Gayed BA, Thoreson GR, Raj GV.

Expert Opin Emerg Drugs. 2013 Dec;18(4):533-50. doi: 10.1517/14728214.2013.864635. Review.

PMID:
24274615
49.

A comparison of pediatric, adolescent, and adult testicular germ cell malignancy.

Cost NG, Lubahn JD, Adibi M, Romman A, Wickiser JE, Raj GV, Sagalowsky AI, Margulis V.

Pediatr Blood Cancer. 2014 Mar;61(3):446-51. doi: 10.1002/pbc.24773. Epub 2013 Sep 17.

PMID:
24106160
50.

Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?

Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF, Bolenz C, Sagalowsky AI, Raj GV, Shariat SF, Kapur P, Margulis V.

J Urol. 2014 Apr;191(4):926-31. doi: 10.1016/j.juro.2013.09.031. Epub 2013 Sep 20.

PMID:
24060642

Supplemental Content

Support Center